Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) was founded in 2016 and is headquartered in Durham, North Carolina, USA, with 33 full-time employees (9/30/2018). It is a pharmaceutical company that focuses on the acquisition of thrombocytopenia drug candidates, Development and commercialization.
Dova Pharmaceuticals (DOVA):
Dova Pharmaceuticals is a pharmaceutical company focused on acquiring, developing and commercializing thrombocytopenia drug candidates.
Dova Pharmaceuticals’ drug candidates include avatrombopag, an orally administered thrombopoietin receptor agonist, which has completed a phase III clinical trial for the treatment of thrombocytopenia in patients with chronic liver disease
Dova Pharmaceuticals (DOVA) investment:
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) was listed on NASDAQ on 6/29/2017 with an issue price of US$17. It issued 4.415 million shares and raised US$75.55 million. The stock code is DOVA.